Clinical Trials Logo

Clinical Trial Summary

The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)


Clinical Trial Description

This will be a Phase 1, randomized, double-blind, placebo-controlled and open-label, active controlled, 4 period, crossover study in healthy male and female subjects under fed conditions.

The study will be double blinded for BIA 5-1058 and placebo and open label for moxifloxacin. The central ECG laboratory and ECG readers will be blinded to study treatment sequence, timepoint, and subject. All subjects will receive each of the following 4 treatments:

- 400 mg BIA 5 1058

- 1200 mg BIA 5 1058

- placebo

- 400 mg moxifloxacin Potential subjects will be screened to assess their eligibility to enter the study between 28 and 3 days prior to the first treatment administration. For each treatment period, subjects will be admitted into the Clinical Research Unit (CRU) on Day 2 and be confined to the CRU until Discharge on Day 4. Each subject will receive a single dose of study medication on Day 1 of each treatment period. There will be a washout of at least 10 days between doses, and subjects will return to the CRU for a Follow-up visit 14 ± 2 days after Period 4 Discharge. The total duration of study participation for each subject from Screening through Follow-up visit) is anticipated to be approximately 80 days.

The start of the study is defined as the date the first enrolled subject signs an Informed Consent Form (ICF). The point of enrollment occurs at the time of subject number allocation. The end of the study is defined as the date of the last subject's last assessment (scheduled or unscheduled). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03489005
Study type Interventional
Source Bial - Portela C S.A.
Contact Ana Santos, BSc., MBA
Phone +351 22 073 2649
Email ana.santos@bial.com
Status Recruiting
Phase Phase 1
Start date April 2018
Completion date September 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT03087084 - RESpiration deTection From Implanted Cardiac Devices in Subjects With Heart Failure (REST-HF) N/A
Recruiting NCT03300791 - Predictive Models of Readmission in Heart Failure N/A
Recruiting NCT03294512 - Pilot and Feasibility Study of a MAWDS (Medications, Activity, Weight, Diet and Symptoms) Heart Failure Mobile Platform N/A
Recruiting NCT03281122 - A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction Phase 1
Recruiting NCT02275819 - Exercise Training in Heart Failure: Changes in Cardiac Structure and Function
Completed NCT03238729 - Proof-of-Concept Study of Heart Habits Application for Patients With Heart Failure N/A
Not yet recruiting NCT03587064 - Comparison of CRT-D and CRT-DX Systems (CRT-NEXT) N/A
Not yet recruiting NCT03629340 - Metformin for PH+HFpEF Phase 2
Not yet recruiting NCT03360448 - AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure Phase 3
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Recruiting NCT02823795 - The Supporting Patient Activation in Transition to Home Intervention N/A
Recruiting NCT02921607 - Development of Scalable New Model(s) Focused on Care Co-ordination and Care Provision for Medically Complex, Co-morbid Chronic Disease Patient Segments Focusing on Heart Failure N/A
Recruiting NCT02674438 - Comparison of Outcomes and Access to Care for Heart Failure Trial Phase 3
Recruiting NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study N/A
Recruiting NCT02877914 - China PEACE 5r-HF Study N/A
Recruiting NCT02911493 - Reducing Sedentary Time in Patients With Heart Failure N/A
Recruiting NCT03013270 - Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure N/A
Recruiting NCT02713126 - Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF (INABLE-Training) Phase 2